Cannabis Science Prepares for the Grand Opening of Its First Two Pre ICO Pharmacies in Prime, High Traffic Areas

IRVINE, CA, Jan. 08, 2018 (GLOBE NEWSWIRE) — Cannabis Science, Inc. (OTC Pink: CBIS), a U.S. company specializing in the development of cannabinoid-based medicines, is pleased to announce that the Company is preparing for the Grand Opening of its first two Pre ICO Pharmacies in California. These pharmacies will be managed through the use of a Pharmacy Automation and Inventory Tracking System.

“Cannabis Science’s Pharmacies are in prime, high traffic areas on Pico Boulevard in Los Angeles and on Ventura Boulevard in the San Fernando Valley. The Company has also been presented with an opportunity to purchase a potentially 60,000 sq. ft. building in Los Angeles, CA. This is where the Company can build its first Cannabis Science Medical Center, including full laboratory facilities, patient intake, and doctor and nurse clinics. We will look at the possible use of the Company’s rare U.S. Federal Government Cage Code Clearance to provide U.S. Federal Government approved Emergency Medical Services,” stated Mr. Raymond C. Dabney, Cannabis Science’s President, CEO, and Co-founder.

“It is possible we will include our sister Company, Crown Baus Capital Corp (OTC: CBCA) in this purchase. Additional space will be leased to physician groups and other medical cannabinoid related health services and well-being providers. I am particularly excited about the Cannabis Science Medical Center, this was always one of our main goals,” stated Mr. Dabney. “This facility will serve as a hub for our activities. Not only will physicians be able to consult directly with patients at the Center, but the Company will also be able to coordinate and expand its global reach and research on cannabinoid-based drugs related to development initiatives through the Cannabis Science Global Research Consortium.

“Our Pharmacies are designed to be state of the art facilities and they will be beautiful. We will showcase the entire Cannabis Science product line, as well as additional products from select vendors that meet the high standards that we have set for our CBIS-branded products,” stated Mr. Dabney. “As part of the Company’s overall drug-development strategy, the Cannabis Science Pharmacies will provide our Company with an important retail sales channel and allow us to interact directly with those who will benefit from our medicines – our patients.”

These new acquisitions offer Cannabis Science a very strong foothold in the medical services industry. In addition, the Company is actively negotiating with its East Coast Associates in Washington, D.C and New York City to expand the CBIS-branded Pharmacies into those areas and expect to announce our progress in the coming months.

The Company launched the Cannabis Science Global Consortium in 2017. This Consortium provides a framework to cooperate and collaborate with stakeholders worldwide. “The Cannabis Science Global Consortium links universities, foundations, corporations, and individuals to share research, ideas, and other relevant information, as well as to implement a cutting-edge research program to develop medicines and delivery mechanisms from bench-to-bedside,” stated Dr. Allen Herman, Cannabis Science’s Chief Medical Officer.

In 2017, Cannabis Science successfully registered to apply for U.S. Federal Government contracts and grants. As part of this registration process, the Company secured its Federal Commercial and Government Entity (CAGE) Code, which is issued by the Department of Defense’s (DoD) Defense Logistics Agency (DLA) CAGE Code Program Office. Cannabis Science is one of the only companies in its industry with the ability to receive U.S. Federal Government contracts and grants. Cannabis Science will use its expertise and relationships with Government Agencies and University Medical Research Groups to further Cannabinoid Pharmaceutical Development, and to reconfigure access to treatment with cannabinoids by designing and building effective and efficient pharmacies and medical clinics staffed by skilled health professionals.

“Cannabis Science is off to a fast start in 2018 and the Company expects to announce new pharmacy acquisitions in the first quarter as we expand from Coast to Coast and then work our way from North to South,” stated Dabney. “With 29 states having some form of Medical Marijuana legalization, and as many as seven more expected to pass Medical Marijuana laws this year, Cannabis Science is stepping up to meet the critical demand and next will be warranting the rest of States to join in this movement based on the medical needs and demands of the patients.”

About Cannabis Science, Inc.

Cannabis Science, Inc. takes advantage of its unique understanding of metabolic processes to provide novel treatment approaches to a number of illnesses for which current treatments and understanding remain unsatisfactory. Cannabinoids have an extensive history dating back thousands of years, and currently, there are a growing number of peer-reviewed scientific publications that document the underlying biochemical pathways that cannabinoids modulate. The Company works with leading experts in drug development, medicinal characterization, and clinical research to develop, produce, and commercialize novel therapeutic approaches for the treatment for illnesses caused by infections as well as for age-related illness. Our initial focus is on cancers, HIV/AIDS, and neurological conditions. The Company is proceeding with the research and development of its proprietary drugs as a part of this initial focus: CS-S/BCC-1, CS-TATI-1, and CS-NEURO-1, respectively.

Forward-Looking Statements

This Press Release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934. A statement containing words such as “anticipate,” “seek,” intend,” “believe,” “estimate,” “expect,” “project,” “plan,” or similar phrases may be deemed “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Some or all of the events or results anticipated by these forward-looking statements may not occur. Factors that could cause or contribute to such differences include the future U.S. and global economies, the impact of competition, and the Company’s reliance on existing regulations regarding the use and development of cannabis-based drugs. Cannabis Science, Inc., does not undertake any duty nor does it intend to update the results of these forward-looking statements. Safe Harbor Statement. The Private Securities Litigation Reform Act of 1995 provides a ‘safe harbor’ for forward looking statements. Certain of the statements contained herein, which are not historical facts are forward looking statements with respect to events, the occurrence of which involved risks and uncertainties. These forward-looking statements may be impacted, either positively or negatively, by various factors. Information concerning potential factors that could affect the company is detailed from time to time in the company’s reports filed with the Securities and Exchange Commission.

Contact Information

Cannabis Science, Inc.
Dr. Allen Herman
Chief Medical Officer
allen.herman@cannabisscience.com
Tel: 1-888-263-0832

Cannabis Science, Inc.
Mr. Raymond C. Dabney
President & CEO, Co-Founder
raymond.dabney@cannabisscience.com
Tel: 1-888-263-0832